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Objective: To report on the unexpected improvement in major biological surrogate markers (CD4T-cell count, HIV RNA 
viral load, and apoptosis level) during the periods of 'brown sugar' heroin intoxication (BSI) in 12 HIV-I-infected 
intravenous drug users, independently of their antiretroviral therapy, compared to  the period of 'brown sugar' heroin 
withdrawal (BSW). 
Methods: The patients were followed prospectively for a total of 417 months over 4 years. Twenty-four episodes of BSI 
and 24 periods of BSW were analyzed. 
Results: (1) BSI: the mean ( tSE) duration was9t1.8 months; at onset, the meantSE CD4T-cell count was 401t88/mm3; 
at the end, an absolute increase of 346 CD4 T-cells/mm3 and a CD4 T-cell count relative variation of +131% was observed. 
Half of the patients showed an increase of CD4 T-cell count of more than 90% during their follow-up. The mean+SE of 
CD8 T-cell count increased significantly by 108%. (2) BSW the mean +SE duration was 8.4t1.3 months; at onset, the 
mean ?SE CD4 T-cell count was 695a78/mm3; at the end, an absolute decrease of 342 CD4 T-cells/mm3 and a CD4 
T-cell count relative variation of -52% was observed. Half of the patients showed a decrease of CD4 T-cell count of more 
than 51%. (3) Circulating viral load appeared to be significantly higher during BSW (median: 452000 Eq RNA/mL) 
than during BSI (median: 52 000 Eq RNNmL); p<O.OI. (4) Similarly, the apoptotic process affecting circulating 
lymphocytes was significantly lower during BSI than during BSW episodes. (5) The 4-year mortality rate was 7%, 
compared with 36% in HIV-positive former drug users (p<O.OOI).  
Conclusions: Taken together, these features suggest that 'brown sugar' heroin could have either immunomodulatory 
or antiretroviral properties. Confirmation of these findings and investigation of the role of the many substances in 'brown 
sugar' heroin are indicated. 
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INTRODUCTION 
Intravenous drug use is the second commonest mode 
of HIV transmission in developed countries. Rapid 
spread of HIV through drug-using groups has been 
reported in Europe, the USA and Asia [l]. Prospective 
studies of HIV infection among drug users are few and 
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their conclusions are controversial [2-lo]. Some studies 
have concluded that continued drug use is an adverse 
influence in AIDS progression in this population 
[8,9,11], but other investigations have not found this 
[4,10,12-141. The latter conclusion is in contradiction 
to the commonly accepted view that opiate addiction 
depresses immune function and increases susceptibhty 
to infection [ 151. Increased morbidity and mortahty 
among drug users from HIV-related bacterial infections 
and tuberculosis have been reported [16-221. Some of 
these infections are related more to the absence of 
sterilization of the injected material than to opiates 
themselves. Up to now, no study has analyzed mor- 
bidity, mortality, survival rate or progression to AIDS 
according to the type of substance intravenously in- 
jected. We feel that this lack has contributed greatly to 
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the inconclusive results of investigations of the 
prognostic significance of drug use in HIV infection. 
We report a prospective study on the temporal vari- 
ations of surrogate markers in intravenous drug addict 
patients taking a non-purified form of heroin known 
as ‘brown sugar’, during both intoxication and with- 
drawal periods. 
PATIENTS AND METHODS 
We included in the study HIV-positive intravenous 
drug users who were regularly followed up for their 
HIV infection: they had periods of intoxication with 
non-purified heroin followed by periods of withdrawal. 
All patients were followed up in the Department of 
Infectious Diseases and data were obtained retrospec- 
tively between September 1991 and January 1996 
(Villeneuve St Georges, France). Among 155 HIV- 
positive patients infected through drug injection 
followed up in the center, 44 were still active drug 
users. Among those, only 12 patients had repeated 
episodes of intoxication and withdrawal, about which 
accurate information was obtained by interview. All 
patients were followed up by one of the authors (every 
3-6 months), and the doctor-patient relationship was 
sufficiently strong to provide precise information. 
Lethality rates were compared between HIV-positive 
active drug users and HIV-positive former drug users, 
as a control group. Information was collected prospec- 
tively from patients during their regular visits. Inform- 
ation included type of intoxication, dose per day, 
period in prison, location of supply and type of heroin. 
Clinical data included CDC stage, HIV-related clinical 
events as well as deaths and cause of death. All patients 
were systematically advised to avoid syringe sharing, 
and were encouraged to enter a detoxification program. 
An intoxication period (IP) was defined as starting 
on a first ‘brown sugar’ heroin (BSH) injection date and 
ending with the total withdrawal of BSH or substitu- 
tion of ‘white’ heroin injection. 
A withdrawal period (WP) was defined as ending 
on the date of renewed BSH injection and starting with 
the last injection of the previous intoxication period. 
Other types of drug abuse, as well as the use of 
methadone substitution, were not considered as 
triggering the start of an IP. None of the patients were 
cocaine injectors or users. The date of infection was 
estimated to be (1) the time from seroconversion when 
observed, or failing this, (2) the last year of syringe 
sharing with other drug users, or, failing this, (3) the 
period of drug use prior to serologic test. 
We recorded CD4 and CD8 T cell-counts, per- 
centage of CD4 and CD8 T-cells among lymphocyte 
total cell count, and p24 antigenemia. For some 
patients, viral load and apoptosis were also determined. 
CD4 and CD8 T-cell counts, viral load and p24 
antigenemia were determined in the same laboratory 
(Departement de Biochimie, Villeneuve St Georges 
Hospital, France), which is periodically controlled for 
quality assurance. 
RNA viral load was assessed retrospectively on 
plasma thawed from -80°C by bDNA technology 
(QUANTIPLEX, HIV RNA 0.2, Chiron, Emeryville, 
CA, USA). We have presented the evolution of 
immunologic markers as follows: the variation, from 
the beginning to the end of a period, of the absolute 
number of CD4 and CD8 T-cells; the percentage 
variation, from the beginning to the end of a period, 
of CD4 and CD8 T-cells; and the variation, from the 
beginning to the end of a period, of the CD4 T-cell 
percentage of lymphocytes. 
T-cells from HIV-infected persons are highly prone 
to apoptosis in vitro both by mitogens and super- 
antigens. In this study, lymphocytes from HIV-infected 
patients were cultivated in a controlled medium or 
stimulated for 24 h by stimuli including ionomycin and 
anti-CD3 monoclonal antibody (Iot 3). Then, apop- 
tosis was quantified by staining nuclei with propidium 
iodide (PI), and FACscan analysis. Cells were incubated 
at room temperature for 5 min in the presence of both 
dyes and then analyzed on a FACScan (Becton 
Dickinson Immunocytometry Systems, San Jose, CA, 
USA) benchtop cytometer with standard argon laser 
settings (488 nm) and filter sets (530-585-nm, and 
>650-nm bypass filters). Data from the cytometer were 
acquired and analyzed with Consort 30 and LYSIS I1 
software (Becton Dickinson Immunocytometry 
Systems), respectively. Single live and dead lymphocytes 
were gated by light scatter parameters, using linear- 
scale amplicifation; red blood cells, debris, and non- 
adherent macrophages were excluded. Fluorescence 
signals were logarithmically amplified with fluor- 
escence compensation [23]. 
Statistical analysis was used to evaluate the variation 
of immunologic markers according to (1) the duration 
of IP and WP, and (2) the level of CD4 T-cell count at  
the beginning of each period. We used the relative 
variation of CD4 T-cell count (i.e. difference in CD4 
T-cell count between the beginning and the end of the 
period divided by CD4 T-cell count at  the beginning 
of the period) by month as the outcome variable. To 
assess the effect of the BSH intoxication (coded 1 
when present and 0 when not), we used the generalized 
linear model, which allowed us to take into account 
intrasubject and intraperiod correlations of these 
measurements. Analysis was performed using the GLM 
procedure implemented in the SAS software (SAS 
Institute, Cary, NC, USA). A survival analysis was 
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performed and probabilities of survival were computed 
according to the Kaplan-Meier product limit method. 
RESULTS 
Twelve HIV-positive intravenous drug user patients 
were included in the study. All of them were male. The 
mean age was 29.6 years, and the mean CD4 T-cell 
count at the beginning of follow-up was 415 
cells/mm3. None of them had HIV-related symptoms. 
Table I shows the year of birth, sex, date of first positive 
HIV test, estimated date of contamination, number of 
months of follow-up, CD4 T-cell count and CDC stage 
at the beginning of follow-up. 
Follow-up accounted for a total of 481 months. At 
the end of follow-up, patients have been estimated to 
be HIV positive for a period ranging from 7 to 11 years. 
Antiretroviral treatment (zidovudine) was given to only 
four patients. In three patients (patient 2, patient 7 and 
patient ll),  zidovudine was prescribed more than 6 
months before inclusion in the present study and 
discontinued at month 3 (M3) in one, at M12 in 
another, and at M5 in the third. The other patients did 
not receive any other treatment or antiretroviral 
therapy. 
During an IP, all patients took BSH in one to three 
injections per day, i.e. 0.5-2 g per day. Most patients 
used to take cannabis and other psychotropic drugs, but 
their use was not related to BSH consumption. Figure 
1 illustrates the time course of the changes and the 
frequency of the estimations of CD4 T-cell count and 
RNA viral load in four demonstrative patients with 
increase of CD4 T-cell count and simultaneous 
decrease of RNA viral load during IPS and decrease of 
CD4 T-cell count and simultaneous increase of RNA 
viral load during WPs. Twenty-four IPS and 24s WP 
were observed and statistically analyzed. 
Table 1 Characteristics of the 12 HIV-positive drug users 
T-cell count 
Intoxication period 
The mean duration of these periods was 9 months 
(range: 2-33 months). Fifty per cent of these periods 
were shorter than or equal to 6 months. Table 2 shows 
the biological parameters and their evolution during 
IPS. The mean variation of the CD4 T-cell absolute 
number was an increase of 346 cells/mm3 (SE: 47.5). 
The mean variation of the CD4 percentage number 
was an increase of 131% (SE: 28.4). In all IPS, except 
one, an increase in CD4 T-cell count was found; the 
exception was a CD4 T-cell count decrease of 40, and 
occurred in a patient who used to take heroin only 
once or twice a week during this period. Apart form 
this, the IP with the lowest progression exhibited a 19% 
increase of CD4 T-cell count (+70 CD4 T-cells). This 
positive variation of CD4 T-cell count was associated 
with an increase in the CD4 T-cell percentage of the 
total lymphocyte count. As for CD4, CD8 T-cell count 
was highly modified and increased during IPS. 
The mean variation of the absolute number of 
CD8 cells was an increase of 392 cells/mm3 (SE: 
109.6). However, in six IPS, CD8 T-cell count 
decreased (-100 to -470 cells/mm3) as the CD4 
T-cell count was rising. The lowest increase in CD8 
T-cell count was 38 cells/mm3 and the highest was 
1466 cells/mm3. Among these 24 IPS, six showed a 
CD8 decrease of -6 to -54% and 18 experienced an 
increase of +3 to +1094%. 
Withdrawal period 
In 12 patients, 24 WPs were observed. The mean 
duration of these periods was 8.4 months (range: 2-22 
months). Fifty per cent of such periods were shorter 
than or equal to 6 months. Table 3 shows the biological 
parameters and their evolution during such periods. 
The mean of the variation of absolute number of CD4 
Patient Year of First HIV- Estimated year Follow-up CD4 T-cell WHO stage 
No. birth Sex positive test of contamination (months) count at entry at entry 
1 1961 M 1988 1985 27 912 A 
2 1957 M 1989 1985 36 246 A 
3 1960 M 1989 1986 45 430 A 
4 1967 M 1989 1985 33 254 A 
5 1963 M 1990 ? 46 47 1 A 
6 1961 M 1987 1984 50 767 A 
7 1962 M 1987 1987 56 262 A 
8 1963 M 1987 1983-87 31 180 A 
9 1965 M 1986 ? 17 420 A 
10 1963 M 1989 1988 61 580 A 
11 1961 M 1989 1986 62 230 A 
12 1963 M 1990 ? 17 234 A 
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Table 2 Variation of biological parameters during the 24 ‘brown sugar’ heroin intoxication periods 
Standard 
Mean ermr Median Range 
Duration of intoxication (months) 9 1.9 6 2-33 
CD4 T-cell count at entry (no. ce l l s /nd)  401 88.6 280 45-828 
CD4 absolute number variation at end of intoxication (no. cells/mm3) 346 47.5 295 -40 to 980 
CD4 percentage variation at end of intoxication YYo) 131 28.4 94 -14 to 655 
Variation of CD4 percentage of lymphocytes (%) +6.0 2 +6.0 - 2  to 15 
CD8 absolute number variation at end of intoxication (no. cells/mm3) 392 109.6 330 -470 to 1466 
CD8 percentage variation at end of intoxication (%) 108 45.7 57 -54 to 1094 
Table 3 Variation of biological parameters during the 24 withdrawal periods 
Standard 
Mean ermr Median Range 
Duration of withdrawal (months) 8.4 1.3 6 2-22 
CD4 T-cell count at entry (no. cells/mm3) 695 78.4 600 230 to 1540 
CD4 absolute number variation at end of withdrawal (no. cells/mm3) -342 45.3 -280 -10 to -905 
Variation of CD4 percentage of lymphocytes (%) 6.7 2 -5 +6 to -20 
CD8 absolute number variation at end of withdrawal (no. cells/mni3) - 523 99.2 -440 +469 to -1430 
CD8 percentage variation at end of withdrawal (%) -39 6.3 -45 +40 to -90 
CD4 percentage variation at end of withdrawal (“Yo) -52 4.7 -51 -5 to -93 
T-cells between the end and beginning of the WP was 
a decrease of 342 cells/mm3 (SE: 45.3). The mean 
variation in the percentage of CD4 T-cells was a 
decrease of 52% (SE: 4.7). All WPs showed a decrease 
in CD4 T-cell number. As for CD4, CD8 T-cell count 
significantly decreased during WPs. The mean 
variation of the absolute number of CD8 cells was a 
decrease of 523 cells/mm3 (SE: 99.2). In three WPs, 
CD8 T-cell count increased from 165 to 469 cells/mm3, 
while CD4 T-cell count was decreasing. The lowest 
decrease in CD8 T-cell count was 10 cells/mm3 and the 
highest was 1430 cells/mm3. In the methadone 
substitution period for the two patients, no increase was 
observed in CD4 or CD8 T-cell count, but there was 
a slight decrease of these two markers. 
Comparison of IP and WP 
Comparisons of CD4 T-cell variation between IP and 
W P  are shown in Table 4. Multivariate analysis showed 
a strong statistical association between ‘brown sugar’ 
intoxication and an increase of CD4 T-cell count as 
well as between ‘brown sugar’ withdrawal and a 
decrease of CD4 T-cell count, even after adjustment for 
intraperiod and intraperson variations. 
P24 antigenemia 
In nine patients, P24 antigenemia was negative during 
all follow-ups. In the three remaining patients, in two 
P24 antigenemia went from positive to negative during 
Table 4 General linear model procedure: comparison of 
CD4 T-cell variation between IP and WP 
Variable F value P value 
Univariate analysis 
Subject 
Period 
Intoxication 
0.44 
3.47 
13.45 
0.92 
0.01 
0.0001 
Multivariate analysis 
Subject 0.53 0.87 
Period 2.11 0.08 
Intoxication 13.45 0.0001 
an IP, and it went from negative to positive during one 
other IP in the third patient. 
Viral load 
Twenty-three quantitative RNA HIV-1 viral load 
measurements were performed in eight of these 
patients, using plasma stored in a - 80°C freezer. 
Mean RNA viral load was 151463 c o p i e s / d  
during IPS, with a range varying from 4500 to 401 486 
copies/ml. Six of 12 RNA viral loads were lower than 
SO 000, and five were lower than 18 000 copies/mL. 
Mean RNA viral load was 426670 copies/mL 
during WF’s, with a range varying from 77000 to 
1 499 600 copies/mL. 
No relationship was observed between HIV RNA 
viral load variation and previous zidovudine treatment. 
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Apoptosis Comparison with controls 
Apoptosis was measured in seven patients. Figure 2 
shows that, with and without stimuli, the intensity of 
apoptosis was significantly decreased during IPS in 
Among 155 HIV-positive patients infected through 
injection, 11 1 had already withdrawn from any drug 
use before the beginning of the study. The CD4 T-cell 
comparison with WPs. 
Medium 
- :  p<o.o1 
0 
0 
count was 342/mm3 at baseline and was similar in 
active drug users and former drug users. Among them, 
lonomycine -
p<o.o1 
0 
lot3 
p<0.05 - 
0 
T 
0 
Figure 2 Comparison of apoptosis of lymphocytes from drug-using HIV-infected persons cultured in medium or stimulated 
for 24 h with ionomycine or anti-CD3 monoclonal antibody (Iot3)) during intoxication and withdrawal periods. 
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Figure 3 Survival curves of HIV-positive active drug users and HIV-positive former drug users over a 5-year period. 
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38 died during the 4-year study period. Among those 
who were active drug users (n=44], only three died 
during the same period. Loss to follow-up was similar 
in the two groups, 16% and 18% respectively. The 4- 
year lethality rate was 36% in the control group, 
compared with 7% in the case group, and the difference 
was highly significant (p<O.OOOl).  Figure 3 shows the 
survival curves of these two groups. 
DISCUSSION 
This study suggests, for the first time, that a link 
between BSH and levels of surrogate markers could 
exist. Three categories of drug users can be identified: 
(1) those who are known to take white heroin or BSH 
regularly without interruption; (2) those with a non- 
accurate interview; and (3) those with an irregular 
consumption and an accurate interview. We selected 
for this investigation drug users whose exposure to 
BSH was intermittent and who could be relied upon 
to give accurate information. 
The main biological feature was the 131% increase 
of CD4 T-cell count during IPS and the 52% decrease 
of CD4 T-cell count during WPs. The increase was 
observed in almost all IPS (except one, in which the 
patient did not inject every day) and the decrease was 
observed in all WPs.  These variations were observed in 
the absence of any antiretroviral therapy or after a long 
duration of antiretroviral therapy, hence leading us to 
exclude such therapy as the cause of the changes. 
Moreover, these variations were independent of the 
duration of intoxication, the duration of withdrawal or 
the CD4 T-cell count at the beginning of each period. 
The highest CD4 T-cell progression (655% improve- 
ment of CD4 T-cell count from baseline) was observed 
with a patient starting with a CD4 T-cell count of 45). 
Similarly, viral load decreased during IPS and increased 
during W p s .  The percentage of apoptosis was lower 
during IPS than during WPs. Clinically, the main 
feature was the survival difference during a 5-year 
period between HIV-positive drug users and HIV- 
positive former drug users. The annual lethality rate in 
all active drug users followed up in the center was 2%. 
Among the 12 patients studied, none of them pro- 
gressed to AIDS or died during the follow-up period. 
An increase in CD4 T-cell count, a low viral load 
and a decrease in apoptosis during IPS lead to the 
hypothesis that one of the components of BSH could 
have an immunomodulatory and/or an antiretroviral 
effect. Though this study was an observational study 
and not a trial in which BSH was given at random, we 
cannot rule out the possibility that drug use could be 
related to the physical wellbeing of the drug users. 
Other confounders could also be lifestyle factors and 
the use of other than injectable heroin. 
The prospective surveys including drug abusers 
irrespective of the type of substance used and method 
of administration have shown different results. Some 
studies have concluded that drug injection is a prog- 
nostic factor [3,8,9,11]. Others came to the conclusion 
that the frequency of drug injection is not a prognostic 
factor for progression to AIDS [4,10,12,13]. However, 
these studies did not present their results according to 
the type of substance abuse and to the IPS and WPs of 
the patients included. Finally, a recent communication 
[25] supports our findings, as the authors concluded 
that the viral load was significantly lower in intravenous 
drug users than in gay men, and among intravenous 
drug users the viral load was significantly lower in 
recent injectors compared with those who had not 
injected recently. 
Further studies interpreting results depending on 
the type of substance and method of administration are 
needed to confirm and elaborate the findings of this 
study. 
Drug abusers in New York, Paris or Rome do not 
use the same substances. Individual observation (data 
not shown) has shown that some of these drug abusers 
using solely white heroin did not exhibit any modific- 
ation of CD4, CD8 T-cells and p24 antigenemia. 
It is important to consider that BSH is non- 
purified heroin, derived from opium. It is composed of 
morphine derivatives (i.e. monoacetylmorphine, acetyl- 
codeine and codeine) and poppy alkaloids (i.e. papa- 
verine, noscapine, meconine and thebain). Moreover, 
many ingredients are added to enhance the effects of 
pure heroin, such as paracetamol, quinine, pheno- 
barbital, mannitol, methaqualone, diazepam or pro- 
caine. These ingredients are variable from one powder 
to another [24]. BSH must be differentiated from pure 
heroin, called ‘white’, which is an acetylate derivative 
from morphine isolated from opium. Through this 
purification process, heroin is purified, alkaloids are 
missing and impurities are scarce. After heroin is 
injected, diacetylmorphine is almost immehately trans- 
formed into monoacetylmorphine, which is then 
transformed into morphine in 10min. Morphine is 
known to produce an in vitro enhancement of HIV 
replication in Kupfer cells, as well as in PBMCs [26,27]. 
The extrapolation of this effect to HIV disease pro- 
gression is not relevant, as many other substances can 
interact with the human immune system. 
Some studies conducted in Italy and the USA 
[28,29] have evaluated the potential antiretroviral 
activity of one of the alkaloids present in the ‘brown 
sugar’: papaverine (PAP). It has been shown that PAP 
significantly inhibits HIV replication by more than 90% 
at levels of 30 pM, with a CDso and an EDSO of, 
respectively, 3 pM and 5.8 pM [29]. Moreover, in 
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addition to this antiretroviral activity, PAP enhances 
phytohemagglutinin-induced interferon production at 
levels of 1-10 pM, and cytomegalovirus Ag-induced 
interferon production at levels of 1-3 pM. PAP did not 
affect IL-2 production or IL-2 receptor expression and 
had an inhibitory effect on mitogenic responses. 
Clinically, in a report involving a limited number of 
AIDS patients [30] recovery of immunologic cutaneous 
responsiveness was noted after oral administration of 
PAP for 4 weeks. This was also associated with a 50% 
improvement in the absolute CD4 T-cell count. PAP 
has been shown to have activity against several human 
viruses [31-331. 
These observations show the need to study the 
components of BSH that inhibit HIV replication and 
interleukin production. The sheer number of relevant 
components of BSH makes such a study difficult to 
perform. This is particularly true since the major effect 
might be due to the combination of several com- 
ponents. Of course, the present study should not be 
interpreted as an incentive or advice to use BSH 
injections to fight AIDS. 
Nevertheless, studies and research should be 
encouraged in this new field of investigation. 
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